CN1454595A - Pharmaceutical composition comprising pyrroloquinoline quinone for curing and preventing fatty liver - Google Patents
Pharmaceutical composition comprising pyrroloquinoline quinone for curing and preventing fatty liver Download PDFInfo
- Publication number
- CN1454595A CN1454595A CN02111549A CN02111549A CN1454595A CN 1454595 A CN1454595 A CN 1454595A CN 02111549 A CN02111549 A CN 02111549A CN 02111549 A CN02111549 A CN 02111549A CN 1454595 A CN1454595 A CN 1454595A
- Authority
- CN
- China
- Prior art keywords
- pqq
- pyrro
- fatty liver
- quinoline quinone
- quinone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 58
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 53
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 53
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 53
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 title description 8
- 239000008194 pharmaceutical composition Substances 0.000 title description 6
- 239000003814 drug Substances 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 150000002148 esters Chemical class 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims description 17
- 230000002265 prevention Effects 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 229910021645 metal ion Inorganic materials 0.000 claims description 2
- 230000008521 reorganization Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 5
- 241000124008 Mammalia Species 0.000 abstract description 3
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
- ADXCEOBGDCQCKM-UHFFFAOYSA-N quinoline-2,3-dione Chemical compound C1=CC=CC2=NC(=O)C(=O)C=C21 ADXCEOBGDCQCKM-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 238000000034 method Methods 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000007788 liquid Substances 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 10
- 239000002775 capsule Substances 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- -1 sterol ester Chemical class 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000375 suspending agent Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 3
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010019842 Hepatomegaly Diseases 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- 241000122249 Methylophaga thalassica Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000003605 opacifier Substances 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000197194 Bulla Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- QPLLSCASVCNANH-UHFFFAOYSA-N N1=CN=C2N=CNC2=C1.N1C=CC=C2C=CC=3C(=C12)C=CN3 Chemical compound N1=CN=C2N=CNC2=C1.N1C=CC=C2C=CC=3C(=C12)C=CN3 QPLLSCASVCNANH-UHFFFAOYSA-N 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000002086 displacement chromatography Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003212 lipotrophic effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229950000470 malotilate Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 235000021476 total parenteral nutrition Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention refers to a medicine combination which can cure and prevent the fatty liver in mammal, especially in human and endotherm. It contains a safe and effective amount of pyrrole & quinoline quinone and/or its acceptable salt and/or ester in pharmacy as the active component, and the acceptable carrier in pharmacy. It has a remarkably curative effect on the fatty liver,
Description
Technical field
The present invention relates to medical domain, more specifically, relate to mammal particularly in people and the homoiothermic animal pharmaceutical composition of treatment and prevention fatty liver.Said composition comprises pyrro-quinoline quinone (PQQ) (or its salt, ester) as active component.
Background technology
Fatty liver (fatty liver) is that a kind of multi-pathogenesis causes that the hepatocyte inner lipid accumulates too much pathological state.Under the different causes of disease, the lipid that is accumulated in the liver can be triglyceride, phospholipid, glycolipid or sterol ester.At fatty liver, particularly in the Fibrotic generation evolution of fat hepatitis regulating liver-QI, modulation on immune status, trophic factor, genetic background, life style and age and sex etc. all play considerable effect, should be considered as the condition element of pathogenesis of fatty liver.Be summarized as follows: drive the fat material want in trophism factor malnutrition, obesity, total parenteral nutrition, the body.Pathogenic microorganism inherited genetic factorss such as biological paathogenic factor virus of fatty liver that chemical paathogenic factor industrial poison, medicine, ethanol endocrine metabolism factor diabetes, hyperlipidemia, trimester of pregnancy occur and antibacterial mainly directly cause a disease by the sudden change or the chromosomal distortion of hereditary material gene.The working environment of spirit, psychology and social modernization is sat few moving life style more, and factors such as the dietary structure of higher fatty acid, high heat factor and life sluggishness are relevant with the generation of fatty liver
The popular situation of fatty liver is as follows: the prevalence scope of bibliographical information fatty liver is quite big, the method that is adopted with Diagnosis of Fatty and check that object is different much relations are arranged.In recent years, along with the progress and the extensive use of Type B ultrasonic technique, carry out the report of healthy population fatty liver generaI investigation more and more many as no wound means with B ultrasonic.China recent years has been carried out a series of investigation to B ultrasonic.For example generally investigate a certain College Teachers in Shanghai, the sickness rate 8.8% of fatty liver; The Beijing area is 11% to 1051 workers' of 4 units B ultrasonic findings of the survey; The Hangzhou, Zhejiang province city is 5.2% to the findings of the survey that comprise factory, office, institute and hospital 3015 workers of 7 units, and wherein the male is 7.06%, and the women is 3.23%.This shows, still be higher at the sickness rate of China's fatty liver, particularly particularly evident in large-and-medium size cities.
The clinical manifestation of fatty liver is as follows: clinically according to the onset emergency, fatty liver can be divided into chronic and acute two big classes, the latter is less.Usually our said fatty liver mainly refers to by the chronic fatty liver due to the factors such as obesity, diabetes and ethanol.Show as the bulla fatty degeneration of liver more on the pathology, become the second largest hepatopathy that is only second to viral hepatitis in developed regions.The onset concealment, the course of disease is very long, generally is optimum process more, and liver histopathology does not often have significant change in the long term, but some cases also can develop into fibrosis and liver cirrhosis.
The same with other chronic hepatopathys, chronic fatty liver clinical manifestation is slight, and does not have feature, the health examination or find when carrying out the liver imaging examination because of other diseases of being everlasting.If symptom occurs, then the most common with hepatomegaly, and the degree of hepatomegaly and its state of an illness weight and inconsistent.The chronic Patients with Fatty Liver of part has loss of appetite, nauseating, weak, hepatalgia, abdominal distention in the course of disease, and upper right abdomen constriction.
At present, the present situation for the Drug therapy of fatty liver is as follows:
Simple fatty liver is the commitment of fatty liver disease, promotes intrahepatic fat to disappear and prevents and treats the generation of complication, prognosis and the quality of life that can obviously improve Patients with Fatty Liver by early time treatment.Clinical and experiment shows that Drug therapy is for the promotion intrahepatic fat and follow disappearing of inflammation, and stops it to the development of hepatic fibrosis liver cirrhosis positive effect to be arranged.
Yet; The existing degrease hepatic of still do not have the active drug of preventing and treating fat hepatitis so far. be mainly used in following liver dysfunction and (or) frank NASH and the capable hepatopath's of alcohol auxiliary curing, mainly contain following: the controversial degrease medicine of the promising degrease medicine of degrease medicine antioxidant choline carnitine orotic acid alkali taurate PGE methionine male deoxycholic acid reduced glutathione malotilate vitamin(e) S commonly used-adenosylmethionine amino acid preparation Matadoxine silymarin
Yet these lipotropic medicines still can not be obtained gratifying effect, and therefore, this area presses for development of new fatty liver treatment safely and effectively and prophylactic agent.
Summary of the invention
Purpose of the present invention just provides the pharmaceutical composition of a kind of treatment and prevention fatty liver, and it contains the pyrro-quinoline quinone (PQQ) of (1) safe and effective amount and/or its pharmaceutically acceptable salt and/or ester as active component, and (2) pharmaceutically acceptable carrier.
In a first aspect of the present invention, the purposes of pyrro-quinoline quinone (PQQ) or its pharmaceutically acceptable salt and/or ester is provided, it is used to prepare the medicine of treatment and prevention fatty liver.
Preferably, described medicine contains the pyrro-quinoline quinone (PQQ) of (1) safe and effective amount and/or its pharmaceutically acceptable salt and/or ester as active component, and (2) pharmaceutically acceptable carrier.
In a preference, the content of described active component is 0.01%-99%.
In another preference, the content of described active component is 0.1%-90%.
In another preference, described medicine also contains the material that is selected from down group: the metal ion of vitamin, needed by human, or its mixture.
In another preference, described pyrro-quinoline quinone (PQQ) be synthetic or reorganization (microbial fermentation comprises gene recombinaton) produce.
In a second aspect of the present invention, a kind of health food is provided, it contains pyrro-quinoline quinone (PQQ) or its pharmaceutically acceptable salt of promising 0.001%-50%.
More preferably, described health food contains pyrro-quinoline quinone (PQQ) or its pharmaceutically acceptable salt of 0.01%-10%.
Description of drawings
Fig. 1 has shown the result of the PQQ product of FPLC method evaluation PQQ standard substance and purification.
Fig. 2 A-2D is a dyeing photo of using mouse liver section behind the PQQ of various dose.
The specific embodiment
In the present invention, use as giving a definition:
Herein, term " contain " expression various compositions can be applied to pharmaceutical composition of the present invention together.Therefore, term " mainly by ... form " and " by ... composition " be included in during term " contains ".
Herein, " pharmaceutically acceptable " composition is to be applicable to people and/or animal and not have excessive bad side reaction (as toxicity, stimulation and allergy), and the material of rational benefit/risk ratio is promptly arranged.
Be enough to obtain the therapeutic response of needs when herein, term " safe and effective amount " refers to use by mode of the present invention and do not have the amount that excessive bad side reaction (as toxicity, stimulation and allergy) has the composition of rational benefit/risk ratio.Obviously, concrete " safe and effective amount " is different because of various factors, as the structure of kind (if any), applied concrete preparation and the chemical compound or derivatives thereof of the subject special state of an illness, patient's body condition, subject mammiferous kind, the course of treatment, the treatment carried out simultaneously.
Herein, " active component " comprises pyrro-quinoline quinone (PQQ) and pharmaceutically acceptable salt and ester.Representational salt comprises (but being not limited to): sodium chloride, potassium iodide, potassium chloride.Representational ester comprises (but being not limited to): the ester that pyrro-quinoline quinone (PQQ) and each seed amino acid, Methanamide etc. form.
Herein, " pharmaceutical carrier " is pharmaceutically acceptable solvent, suspending agent or the excipient that is used for pyrro-quinoline quinone (PQQ) is sent to the animal or human.Carrier can be a liquid or solid, can select according to administering mode.
Herein, " fatty liver " refers in the mammal that Different types of etiopathogenises causes that the hepatocyte inner lipid accumulates too much pathological state
The inventor of the present invention is surprised to find that pyrro-quinoline quinone (PQQ) (a kind of known compound) can lower the fat content of animal body fatty liver significantly, thereby effectively prevents and treat fatty liver through research for many years.Finished the present invention on this basis.
Pyrro-quinoline quinone (PQQ) finds from microorganism that the earliest its crystal structure and chemosynthesis all solve.Find also have pyrro-quinoline quinone (PQQ) to exist in the higher eucaryote body at present.Pyrro-quinoline quinone (PQQ) is the prothetic group of multiple important enzyme in the antibacterial, and can influence respiratory chain function and interior free yl level.Find the mice poor growth that pyrro-quinoline quinone (PQQ) lacks under study for action, reproductive performance is poor, and is easy to generate arthritis, therefore has the people to think that pyrro-quinoline quinone (PQQ) is one of nutrient substance essential in the body.
Before the present invention, pyrro-quinoline quinone (PQQ) is considered to have following 4 kinds of major physiological functions: (1) antioxidation; (2) hepatic injury that causes of contratoxin plays protective action; (3) accelerate alcoholic acid degraded; (4) short nerve growth effect.
Studies show that (pyrroloquinoline quinone PQQ) has the function of fat content in the good reduction liver to pyrrolo-quinoline purine quinone.In with the experiment of purification pyrro-quinoline quinone (PQQ) treatment fatty liver mouse model, also observe significant curative effect.
It can be natural, non-natural being used for pyrro-quinoline quinone (PQQ) of the present invention.Preferably, described pyrro-quinoline quinone (PQQ) be synthetic or fermentation (microbial fermentation comprises gene recombinaton) produce.
In the world, pyrro-quinoline quinone (PQQ) is mainly chemically synthetic, general with the skeleton of tyrosine molecule as carbon and nitrogen, intermediate by a dopaquinone, obtain pyrro-quinoline quinone (PQQ) [Hendrickson and deVries through series reaction, 1982, J.Org.Chem.47:1148-1150; Gainor andWeinreb, 1982, J.Org.Chem.47:2833-2837; Buchi et al., 1985, J.Am.Chem.Soc.107:5555-5556; Gainor and Weinreb, 1982, J.Org.Chem.46:4317-4319].Yet there are technical problems such as step is many, cost is high, byproduct of reaction is not easily separated in the method for these chemosynthesis.
The another kind of common method that obtains pyrro-quinoline quinone (PQQ) is to utilize to have a liking for methanol antibacterial itself and can synthesize pyrro-quinoline quinone (PQQ), by fermenting and isolating method acquisition pyrro-quinoline quinone (PQQ).
A. dosage
In the present invention, the dosage to pyrro-quinoline quinone (PQQ) is not particularly limited available any proper dosage.The type of carrier and quantity also can be very inequality, and this depends on homoiothermic animal or people's kind, body weight and fatty liver symptom to be treated etc.Generally, suitable content is the 0.01%-99% that pyrro-quinoline quinone (PQQ) accounts for the pharmaceutical composition gross weight, preferably 0.1-90%.When the treatment fatty liver, the effective dosage ranges of PQQ is generally 0.01-50 mg/kg sky or higher, preferably is 0.1-5 mg/kg sky.
Dosage device comprises a kind of PQQ chemical compound, perhaps the formed mixture of chemical compound of this PQQ chemical compound and other treatment fatty liver.Dosage device also can contain diluent, filler, carrier etc.Dosage unit is solid or gel form, as pill, tablet, capsule etc., or liquid form, they are fit to oral administration, rectally, topical or parenteral or intravenous administration.
B. dosage form
Peroral administration solid composite of the present invention can adopt forms such as tablet, pill, capsule, powder, granule.Mixed active substance and at least one inert diluent more than a kind or a kind in these solid composites, for example, lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline Cellulose, starch, polyvinylpyrrolidone, agar, pectin, aluminosilicate magnesium, magnesium aluminate.Also can make the additive that contains in the compositions except inert diluent according to common method, for example, cosolvents such as stabilizing agents such as disintegrating agents such as lubricants such as magnesium stearate, glycolic cellulose calcium, lactose, glutamic acid or aspartic acid.Tablet or pill in this way also can be as required, sugar-coat such as sucrose, gelatin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose phthalate or gastric solubility, enteric film on its outer wrap.
Peroral administration fluid composition comprises the opacifiers that allows on the medicament, solution, suspending agent, syrup, elixir etc., and normally used inert diluent comprises Purified Water, ethanol.Except inert diluent, also can comprise auxiliary agents such as wetting agent, suspending agent, sweeting agent, correctives, aromatic and antiseptic in the said composition.
Para-oral injection comprises sterile aqueous or non-aqueous solution agent, suspending agent and opacifiers.Comprise injection in aqueous solution agent and the suspending agent with distilled water and normal saline.Comprise propylene glycol in water-insoluble solution and the suspending agent, Polyethylene Glycol, cocoa butter, olive oil, Semen Ricini wet goods vegetable oil, alcohols such as ethanol, arabic gum, Tween 80 (trade name) etc.Also can comprise isotonic agent, antiseptic, wetting agent, emulsifying agent, dispersant, stabilizing agent (for example, lactose), cosolvent (for example, glutamic acid, aspartic acid) in these compositionss.With bacteriological filtration membrane filtration above-mentioned composition, be used biocide again and just can reach aseptic purpose.Then, utilize above-mentioned composition to make aseptic solid composite, water or aseptic injection just can be used with dissolution with solvents before use.
Can be used for preparing pharmaceutically acceptable carrier peroral dosage form of the present invention, concrete and excipient example,, in 297 (JIUYUE was authorized Robert on the 2nd in 1975) description is arranged in U.S. Patent No. 3,903.Be used to make the technology and the compositions of useful dosage form of the present invention, description is arranged in following document: 7 kinds of modern preparations (7 ModernPharmaceutics).The 9th and 10 chapter (Banker ﹠amp; Rhodes edits, and 1979); People such as Lieberman, pharmaceutical dosage form: tablet (Pharmaceutical Dosage Forms:Tablets) (1981); And Ansel, pharmaceutical dosage form introduction (Introduction to Pharmaceutical Dosage Forms) 2 editions (1976).
C. Therapeutic Method
Therapeutic Method can be to treat any suitable effective ways of concrete fatty liver disease.Treatment can be oral administration, rectally, topical, parenteral, intravenous administration.The method of using the effective dose medicine also depends on fatty liver degree to be treated.It is believed that by with the chemical compound of suitable carriers, other treatment fatty liver or make things convenient for the diluent of administration to prepare, and the parenteral Therapeutic Method by intravenous, subcutaneous or intramuscular administration, be with the method for optimizing of compound administration in homoiothermic animal.
Pyrro-quinoline quinone (PQQ) of the present invention also can with the medicine and the coupling of adjunctive therapeutic material of other treatment fatty liver, so that therapeutic effect further to be provided.
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:ColdSpring Harbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.
Embodiment 1
The foundation of pyrro-quinoline quinone (PQQ) detection method
In the present invention, use two kinds of methods of NBT development process and FPLC to detect the pyrroloquinoline quinone content.
The NBT method utilizes pyrro-quinoline quinone (PQQ) to make the character of NBT (chlorination nitro blue tetrazolium) chemical colour reaction in alkaline solution, can detect the content (can detect the above pyrro-quinoline quinone (PQQ) of 10ng) of pyrro-quinoline quinone (PQQ) in the mixture quantitatively.
Concrete operations are as follows: pyrro-quinoline quinone (PQQ) sample to be measured or standard substance add and contain 25ul bovine serum albumin (40mg/ml) 400ul water, and every duplicate samples adds 1.6ml and surveys the buffer (NBT+1.6M glycine buffer) of living, mixing.Lucifuge is incubated 45 minutes for 37 degrees centigrade, measures the absorbance value of 530 nanometers.Do standard curve in view of the above, calculate the content of pyrro-quinoline quinone (PQQ) in the testing sample.
The FPLC method utilizes pyrro-quinoline quinone (PQQ) specific eluting position and peak area in the FPLC-Q post to measure the existence and the content of pyrro-quinoline quinone (PQQ).Testing sample or standard substance 10-100ul are splined on the high-effect ionic displacement chromatography post of the last RESOURE-Q of FPLC, behind the unconjugated composition of A liquid flush away, amount with 20 times of column volumes, carry out by gradient elution (the A liquid: 20mM Tris-HCl of A liquid to B liquid, pH8.0, B liquid: the A liquid that contains 1M NaCl), this material of pyrro-quinoline quinone (PQQ) is to be come out by eluting when the B liquid hold-up reaches 21-25%.According to the area of standard and this position absworption peak of testing sample, calculate the content of pyrro-quinoline quinone (PQQ) in the testing sample.
Embodiment 2
The preparation of pyrro-quinoline quinone (PQQ)
The fermentation of A, pyrro-quinoline quinone (PQQ)
The common method that obtains pyrro-quinoline quinone (PQQ) is to utilize to have a liking for methanol antibacterial itself and can synthesize pyrro-quinoline quinone (PQQ), by fermenting and isolating method acquisition pyrro-quinoline quinone (PQQ).Can directly use Methylophagathalassica bacterial strains such as (ATCC#33145), also the improved strain that can use PQQ output further to provide.Concrete grammar is as follows.
Methylophaga thalassica (ATCC#33145) by changing methanol concentration (0.1-7%), filters out a bacterial strain, and the expression of PQQ reaches 2.0mg/L by 0.5mg/L, with this bacterial strain called after GCpqq303.
Groped under the multiple expression condition, the GCpqq303 bacterial strain is expressed the variation of pyrro-quinoline quinone (PQQ) output in a small amount, mainly comprises: a) incubation time; B) iron ion content in the culture medium; C) in the culture medium magnesium ion content etc. to expressing the influence of output in a small amount.Concrete parameter to the influence of PQQ output referring to table 1.Final definite expression condition is: culture medium (0.3% (NH
4)
2SO
4, 0.14%KH
2PO
4, 0.3%Na
2HPO
4, 0.01%MgSO
4, 0.05%FeCl
3, 0.8% methanol), cultivated 14 days for 30 degrees centigrade.Carry out expressing the about 3～4mg/L of the expression of acquisition more than three times in a small amount.Each parameter of table 1 condition of culture is to the influence of microbial fermentation PQQ output
Experiment is to add on the basis of minimal medium or reduce some composition and carry out, the consisting of of minimal medium: 0.3% (NH
4)
2SO
4, 0.14%KH
2PO
4, 0.3%Na
2HPO
4, 0.02%MgSO
4, 0.03%FeCl
3, 0.8% methanol.Cultivate and measured the influence of ferrum and magnesium ion in 14 days PQQ output.
| Incubation time (my god) | PQQ output (mg/L) | ??FeCl 3Content (%) | PQQ output (mg/L) | ?MgSO 4Content (%) | PQQ output (mg/L) |
| ????1-7 | ????≈0 | ????0 | ????0.04 | ????0 | ????0.07 |
| ????8 | ????0.3 | ????0.005 | ????0.1 | ????0.005 | ????1.22 |
| ????9 | ????0.7 | ????0.01 | ????1.4 | ????0.01 | ????3.81 |
| ????10 | ????1.2 | ????0.03 | ????2.14 | ????0.02 | ????2.09 |
| ????11 | ????1.56 | ????0.05 | ????3.18 | ????0.05 | ????1.65 |
| ????12 | ????1.87 | ????0.1 | ????1.87 | ????0.1 | ????0.87 |
| ????13 | ????2.11 | ||||
| ????14 | ????2.12 | ||||
| ????15 | ????2.04 |
B. the purification of pyrro-quinoline quinone (PQQ)
Fermented liquid supernatant is adsorbed in after the centrifugal filtration on the FPLC-Q post through boiling, and through the salt gradient eluting, collects active peak.The pyrro-quinoline quinone (PQQ) that obtains detects (see figure 1) through the FPLC method, and purity is more than 90%, and yield is 56%.
Embodiment 3
Pyrro-quinoline quinone (PQQ) is to the treatment and the preventive effect of alcoholic fatty liver
Kunming mice is divided into 10 groups, and 12 every group, male and female half and half, average weight are 25 grams.The grouping situation sees the following form, and wherein concrete experimental technique is described below: it is that alcohol concentration is 56% Chinese liquor 0.25ml/ days that ethanol is irritated stomach, carries out 15 days, builds up chmice acute alcoholic fatty liver model.PQQ is divided into treatment group and prevention group, and wherein treatment group is to build up the back at the fatty liver model to treat to irritate stomach or intraperitoneal injection, carries out 30 days; The prevention group is gastric infusion PQQ when ethanol filling stomach is set up fatty liver, carries out 30 days, measures the preventive effect of PQQ to fatty liver.
Animal experiment is got mice blood and liver after finishing, and measures ALT (alanine transaminase), GLU (glucose), GOT (aspartic transaminase), BUN (carbamide) and CRF (kreatinin) in the blood.Mouse liver with hematoxylin daybreak (she) red (HE) dyeing, is observed the formation of fat vacuole in the mouse liver through paraffin section, determines the order of severity of fatty liver.
| Group number | Group name | Explanation |
| 1 | The fatty liver model | Ethanol is irritated stomach |
| 2 | PQQ treatment group | The fatty liver model, PQQ lumbar injection (5mg/kg days) |
| 3 | PQQ treatment group | The fatty liver model, PQQ lumbar injection (0.5mg/kg days) |
| 4 | PQQ treatment group | The fatty liver model, PQQ lumbar injection (0.1mg/kg days) |
| 5 | PQQ treatment group | The fatty liver model, PQQ gastric infusion (5mg/kg days) |
| 6 | PQQ treatment group | The fatty liver model, PQQ gastric infusion (0.5mg/kg days) |
| 7 | PQQ treatment group | The fatty liver model, PQQ gastric infusion (0.1mg/kg days) |
| 8 | PQQ prevention group | PQQ gastric infusion (5mg/kg days) ethanol is simultaneously irritated stomach |
| 9 | PQQ prevention group | PQQ gastric infusion (0.5mg/kg days) ethanol is simultaneously |
| 10 | PQQ prevention group | PQQ gastric infusion (0.1mg/kg days) ethanol is simultaneously irritated stomach |
Found that ALT, GLU, GOT, BUN and CRF do not have significant change (data do not provide) in each group, illustrate that the liver function of each experimental mice and renal function keep normal.
Each finds after organizing the mouse liver section statining that the liver cell nuclear that acute alcohol is irritated stomach fatty liver model has tangible fat vacuole to have (Fig. 2 A), low dose therapy group 7 DeGrains (Fig. 2 B) on every side.Do not have cavity (Fig. 2 D) around the normal mouse nucleus, can see obviously that in treatment group 6 perinuclear cavity obviously reduces (Fig. 2 C), (group 2,3,4,5,8,9,10) all finds to have the obvious alleviation of fatty liver in other each groups.Illustrate that PQQ not only has therapeutical effect but also preventive effect is arranged alcoholic fatty liver.
Embodiment 4
Pyrro-quinoline quinone (PQQ) capsule method for making and dosage
Prescription:
Pyrro-quinoline quinone (PQQ) 1g
PEG400 200g
Make 1000 capsules altogether, each capsule includes principal agent 1mg (promptly 0.5%).
Earlier the PEG400 of pyrro-quinoline quinone (PQQ) with 1/8 amount mixed.Pulverize with colloid mill, the PEG400 that adds surplus then is miscible.It is standby that other joins gelatin solution.Under the condition of room temperature relative humidity 40%, capsule is that medicinal liquid and gelatin are fully acted at automatic rotation rolling capsule machine, then at 28 degrees centigrade, under the condition of relative humidity 40%, finishes whole preparation after dry 20 hours.
Similarly, can make that the pyrroloquinoline quinone content can be low to moderate 0.05% or lower in the capsule, also high to 5% or higher.When the treatment fatty liver, the effective dosage ranges of PQQ is generally 0.01-50 mg/kg sky, preferably is 0.1-5 mg/kg sky.
Embodiment 5
The preparation of health food (oral liquid)
Raw materials such as PQQ, vitamin and trace element, essential amino acids and water are made into oral liquid, and wherein PQQ content is 0.01%.
All quote in this application as a reference at all documents that the present invention mentions, just quoted as a reference separately as each piece document.Should be understood that in addition those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims institute restricted portion equally.
Claims (8)
1. the purposes of pyrro-quinoline quinone (PQQ) or its pharmaceutically acceptable salt is characterized in that, is used to prepare the medicine of treatment and prevention fatty liver.
2. purposes as claimed in claim 1 is characterized in that, described medicine contains the pyrro-quinoline quinone (PQQ) of (1) safe and effective amount and/or its pharmaceutically acceptable salt and/or ester as active component, and (2) pharmaceutically acceptable carrier.
3. purposes as claimed in claim 2 is characterized in that, the content of described active component is 0.01%-99%.
4. purposes as claimed in claim 3 is characterized in that, the content of described active component is 0.1%-90%.
5. purposes as claimed in claim 1 is characterized in that, described medicine also contains the material that is selected from down group: the metal ion of vitamin, needed by human, or its mixture.
6. purposes as claimed in claim 1 is characterized in that, described pyrro-quinoline quinone (PQQ) be synthetic or reorganization produce.
7. a health food is characterized in that, it contains pyrro-quinoline quinone (PQQ) or its pharmaceutically acceptable salt and/or the ester of promising 0.001%-50%.
8. health food as claimed in claim 7 is characterized in that, it contains pyrro-quinoline quinone (PQQ) or its pharmaceutically acceptable salt and/or the ester of 0.01%-10%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021115494A CN1224390C (en) | 2002-04-29 | 2002-04-29 | Pharmaceutical composition comprising pyrroloquinoline quinone for curing and preventing fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021115494A CN1224390C (en) | 2002-04-29 | 2002-04-29 | Pharmaceutical composition comprising pyrroloquinoline quinone for curing and preventing fatty liver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1454595A true CN1454595A (en) | 2003-11-12 |
| CN1224390C CN1224390C (en) | 2005-10-26 |
Family
ID=29256822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021115494A Expired - Fee Related CN1224390C (en) | 2002-04-29 | 2002-04-29 | Pharmaceutical composition comprising pyrroloquinoline quinone for curing and preventing fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1224390C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103239451A (en) * | 2012-02-10 | 2013-08-14 | 上海医学生命科学研究中心有限公司 | Application of pyrroloquinoline quinone in treatment and/or prevention of liver fibrosis |
| CN103525639A (en) * | 2013-10-22 | 2014-01-22 | 北京普利耐特生物科技有限公司 | Pyrroloquinoline quinone-containing wine |
| CN103598484A (en) * | 2013-12-02 | 2014-02-26 | 中国农业科学院饲料研究所 | Forage additive for preventing egg-laying hen fatty liver syndrome and application thereof |
-
2002
- 2002-04-29 CN CNB021115494A patent/CN1224390C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103239451A (en) * | 2012-02-10 | 2013-08-14 | 上海医学生命科学研究中心有限公司 | Application of pyrroloquinoline quinone in treatment and/or prevention of liver fibrosis |
| CN103525639A (en) * | 2013-10-22 | 2014-01-22 | 北京普利耐特生物科技有限公司 | Pyrroloquinoline quinone-containing wine |
| CN103525639B (en) * | 2013-10-22 | 2015-09-16 | 北京普利耐特生物科技有限公司 | A kind of wine containing Pyrroloquinoline quinone |
| CN103598484A (en) * | 2013-12-02 | 2014-02-26 | 中国农业科学院饲料研究所 | Forage additive for preventing egg-laying hen fatty liver syndrome and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1224390C (en) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103462025A (en) | Health food assisting in reducing blood fat and preparation method and application thereof | |
| CN1224383C (en) | Blood sugar reducing compound | |
| CN1931874A (en) | Prepn process, medicine prepn and medicinal use of ginseng glycopeptide | |
| CN1092986C (en) | CoA oral preparation for reducing blood fat and its preparation method | |
| CN1224390C (en) | Pharmaceutical composition comprising pyrroloquinoline quinone for curing and preventing fatty liver | |
| CN1718566A (en) | Ferulaic acid and its sodium salt used for preventing and treating senile dementia medicine | |
| CN1167421C (en) | Medicine composition containing pyrroloquinolinequinone for treating saturnism | |
| CN1248698C (en) | Drug for treating coronary heart disease or coronary disease and cardiac insufficiency, and its preparation method | |
| CN1163227C (en) | Application of tanhin polyphenolic B magnesium in preparing medicine for treating chronic hepatosis | |
| CN1398861A (en) | Prepn and application in preparing medicine of Fraxinus general coumarin | |
| CN1504191A (en) | Cucurbitacin lipsome preparation method and formulation | |
| CN101199492A (en) | Application of oligomerization xylose and xylito in coating slice coating | |
| CN1836684A (en) | Silktree albizzia general saponin and its extraction method, pharmaceutical use of the said composition and medicine preparation | |
| CN1080855A (en) | Anticarcinogenic vitamin and mineral complex prescription | |
| CN1297273C (en) | Pyrroloquinoline containing composition for enriching zinc and reducing plumbum | |
| CN107281199A (en) | The application and medicine of N acetyl D Glucosamines and its drug acceptable salt in treatment virus hepatitis medicine is prepared | |
| CN1679914A (en) | Medicinal composition of induced glutathione and ebeselen | |
| CN106563038B (en) | Taurine and fat-soluble tea polyphenol compound composition, preparation method and application thereof | |
| CN113440574B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating viral myocarditis | |
| CN1686150A (en) | Notoginseng total saponin slow release preparation | |
| CN100421672C (en) | Compound lentinan preparation for antitumour and its preparing method | |
| CN101053598A (en) | Medicinal composition for treating cardio-cerebralvascular diseases and diabetes | |
| CN1481796A (en) | Medication for adiposity | |
| CN1267095C (en) | Application use of dihydromyricetrin | |
| CN1256942C (en) | Application of dihydromyricetrin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20031112 Assignee: Changmao Biochemical Engineering Co., Ltd. Assignor: Shanghai Medicine Biotic Science Research Centre Co., Ltd. Contract record no.: 2010320000200 Denomination of invention: Pharmaceutical composition comprising pyrroloquinoline quinone for curing and preventing fatty liver Granted publication date: 20051026 License type: Exclusive License Record date: 20100310 |
|
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Changmao Biochemical Engineering Co., Ltd. Assignor: Shanghai Medicine Biotic Science Research Centre Co., Ltd. Contract record no.: 2010320000200 Date of cancellation: 20130226 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHUCHENG HAOTIAN PHARM. CO., LTD. Free format text: FORMER OWNER: SHANGHAI MEDICINE BIOTIC SCIENCE RESEARCH CENTRE CO., LTD. Effective date: 20131010 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200032 XUHUI, SHANGHAI TO: 262218 WEIFANG, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20131010 Address after: The 262218 city in Shandong province Xin Xing town resident Patentee after: Zhucheng Haotian Pharm Co., Ltd. Address before: 200032 No. 130, Dongan Road, Shanghai, Xuhui District Patentee before: Shanghai Medicine Biotic Science Research Centre Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051026 Termination date: 20200429 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |